Testino Gianni, Leone Silvia, Borro Paolo
Gianni Testino, Paolo Borro, Centro Alcologico Regionale-Regione Liguria, Alcoholic Unit, Department of General Internal and Specialist Medicine, IRCCS AOU San Martino-National Institute for Cancer Research-IST, 16100 Genova, Italy.
World J Gastroenterol. 2014 Nov 21;20(43):15943-54. doi: 10.3748/wjg.v20.i43.15943.
It is well recognized that one cause of chronic liver disease and hepatocellular carcinoma (HCC) is alcohol consumption. Research in Italy and the United States concludes that the most common cause of HCC (responsible for 32% to 45% of HCC) is alcohol. It has recently been shown that a significant relationship between alcohol intake, metabolic changes, and hepatitis virus infection does exist. Alcohol may be a factor in the development of HCC via direct (genotoxic) and indirect mechanisms (cirrhosis). There is only one way of diagnosing HCC, which is early identification through surveillance, when curative treatments become possible. After stopping alcohol intake the risk of liver cancer decreases by 6% to 7% a year, and an estimated time period of 23 years is also needed. Therefore, surveillance is also important in former drinkers and, in our opinion, independently from the presence of compensated cirrhosis. In cases of very early stage (VES) and early stage with portal hypertension, liver transplantation is the optimal option; and in cases of associated disease, percutaneous ethanol injections, radiofrequency and microwave ablation are the ideal treatments. Despite the possibility of detecting microvascular invasion with HR, several studies and some randomized controlled trials revealed that overall survival and DSF rates in patients with VES HCC are much the same after ablation and HR. Therefore, ablation can be regarded as a first-line choice for patients with VES HCC. It is important to emphasize that the choice of treatment should be weighed carefully in the context of a multidisciplinary cancer team.
众所周知,慢性肝病和肝细胞癌(HCC)的一个病因是饮酒。意大利和美国的研究得出结论,HCC最常见的病因(占HCC的32%至45%)是酒精。最近有研究表明,酒精摄入量、代谢变化和肝炎病毒感染之间确实存在显著关系。酒精可能通过直接(基因毒性)和间接机制(肝硬化)成为HCC发生发展的一个因素。诊断HCC只有一种方法,即通过监测进行早期识别,此时才有可能进行根治性治疗。戒酒之后,肝癌风险每年降低6%至7%,而且这一过程预计需要23年。因此,监测对于既往饮酒者也很重要,而且在我们看来,与是否存在代偿性肝硬化无关。对于极早期(VES)和伴有门静脉高压的早期病例,肝移植是最佳选择;对于伴有相关疾病的病例,经皮乙醇注射、射频和微波消融是理想的治疗方法。尽管HR有可能检测到微血管侵犯,但多项研究和一些随机对照试验表明,VES HCC患者接受消融和HR后的总生存率和无病生存率大致相同。因此,消融可被视为VES HCC患者的一线选择。必须强调的是,应在多学科癌症治疗团队的背景下仔细权衡治疗方案的选择。